Eurofins completes $400M Element Life Sciences NA acquisition

Eurofins Scientific said it has completed its acquisition of Element Materials Technology's Life Sciences Testing Services business in North America, with the closing taking place on October 1, 2026, for an enterprise value of $400 million restated on the closing disclosure.

Eurofins closed its purchase of Element Materials Technology's North American Life Sciences Testing Services business on October 1, 2026 — a company closing disclosure, not another pending-deal update.

Closed on October 1

Eurofins Scientific SE (EUFI.PA; Paris: ERF) said it has completed the acquisition of the Life Sciences Testing Services business in North America of Element Materials Technology ("Element"), with the closing taking place on October 1, 2026. The closing release is posted on Eurofins' media-centre press-releases page. The October 2 closing release restates that the transaction was announced on July 20, 2026 for an enterprise value of $400 million.

The closing release describes the acquired business as providing Biopharma product testing, Environmental testing, and Food testing services through a network of 27 laboratories and facilities. It employs approximately 750 staff and is expected to generate annual revenues of over $150 million in 2026, with profitability similar to the Eurofins Group average — company expectations restated on the closing disclosure, not independently verified run-rate results.

The company says the acquired operations join Eurofins' BioPharma and Life businesses in North America and extend the laboratory network into key regions of the United States and Canada where Eurofins has historically been underrepresented. Clients are to gain access to the broader Eurofins service offering, and the acquired laboratories are to benefit from Eurofins' hub-and-spoke laboratory networks, with integration focused on continuity of service. CEO Dr Gilles Martin framed the close as welcoming Element's North American Life Sciences Testing Services teams onto Eurofins' "well invested, efficient and digital laboratories platform."

What the July 2026 agreement set

The October 2 closing release confirms consummation and restates the $400 million enterprise value. That same $400 million figure was disclosed when Eurofins announced an agreement on July 20, 2026, with the transaction then subject to customary conditions, including regulatory approvals, and expected to close in the fourth quarter of 2026 — now sealed by the October 1 close.

Readers should keep the layers straight: the October 2 closing release seals consummation of the October 1 close and restates $400 million enterprise value; July 20 is the agreement announcement and then-expected Q4 close context.

Distinct from the UL Solutions / Eurofins E&E closing

Separately on October 1, 2026, UL Solutions completed its acquisition of Eurofins Scientific's electrical and electronics business — a different closing already covered separately on TickerGrove. That deal is UL Solutions buying Eurofins E&E; this story is Eurofins buying Element's Life Sciences Testing Services business in North America for $400 million.

Why the close matters

An October 2 closing release turns the previously announced Element Life Sciences North America purchase into a sealed close for a Euronext-listed testing company deepening its core "testing for life" footprint in North America. For readers tracking laboratory-testing M&A, the distinction that matters is sealed closing versus signed-but-not-closed — this one closed on October 1 per Eurofins' October 2 closing release.

Sources & evidence

Primary closing disclosure: Eurofins Completes the Acquisition of Element Materials Technology's Life Sciences Testing Services Business in North America (Eurofins IR; close took place October 1, 2026). Supporting announce: Eurofins agrees to acquire Element Materials Technology's Life Sciences Testing Services business in North America (July 20, 2026; same $400 million enterprise value; then expected Q4 2026 close).